CN1327844C - 包含双膦酸类化合物和hmg－coa还原酶抑制剂的组合疗法 - Google Patents

包含双膦酸类化合物和hmg－coa还原酶抑制剂的组合疗法 Download PDF

Info

Publication number
CN1327844C
CN1327844C CNB038213338A CN03821333A CN1327844C CN 1327844 C CN1327844 C CN 1327844C CN B038213338 A CNB038213338 A CN B038213338A CN 03821333 A CN03821333 A CN 03821333A CN 1327844 C CN1327844 C CN 1327844C
Authority
CN
China
Prior art keywords
hmg
coa reductase
reductase inhibitor
bisphosphonate
bisphosphonates
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CNB038213338A
Other languages
English (en)
Chinese (zh)
Other versions
CN1681515A (zh
Inventor
C·M·鲍奇布朗
A·斯宾塞
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis AG filed Critical Novartis AG
Publication of CN1681515A publication Critical patent/CN1681515A/zh
Application granted granted Critical
Publication of CN1327844C publication Critical patent/CN1327844C/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
    • A61K31/663—Compounds having two or more phosphorus acid groups or esters thereof, e.g. clodronic acid, pamidronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CNB038213338A 2002-09-09 2003-09-08 包含双膦酸类化合物和hmg－coa还原酶抑制剂的组合疗法 Expired - Fee Related CN1327844C (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0220885.8 2002-09-09
GBGB0220885.8A GB0220885D0 (en) 2002-09-09 2002-09-09 Organic compounds

Publications (2)

Publication Number Publication Date
CN1681515A CN1681515A (zh) 2005-10-12
CN1327844C true CN1327844C (zh) 2007-07-25

Family

ID=9943733

Family Applications (1)

Application Number Title Priority Date Filing Date
CNB038213338A Expired - Fee Related CN1327844C (zh) 2002-09-09 2003-09-08 包含双膦酸类化合物和hmg－coa还原酶抑制剂的组合疗法

Country Status (9)

Country Link
US (2) US20060234985A1 (enExample)
EP (1) EP1539186A1 (enExample)
JP (1) JP2006500401A (enExample)
CN (1) CN1327844C (enExample)
AU (1) AU2003270154A1 (enExample)
BR (1) BR0314081A (enExample)
CA (1) CA2497182A1 (enExample)
GB (1) GB0220885D0 (enExample)
WO (1) WO2004024165A1 (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0327742D0 (en) * 2003-11-28 2003-12-31 Isis Innovation Novel uses of known drugs
US8012949B2 (en) 2004-10-08 2011-09-06 The Board Of Trustees Of The University Of Illinois Bisphosphonate compounds and methods with enhanced potency for multiple targets including FPPS, GGPPS, and DPPS
US7358361B2 (en) 2004-10-08 2008-04-15 The Board Of Trustees Of The University Of Illinois Biophosphonate compounds and methods for bone resorption diseases, cancer, bone pain, immune disorders, and infectious diseases
US7687482B2 (en) 2006-03-17 2010-03-30 The Board Of Trustees Of The University Of Illinois Bisphosphonate compounds and methods
FR2903312B1 (fr) 2006-07-05 2008-09-26 Univ Aix Marseille Ii Utilisation d'inhibiteurs d'hmg-coa reductase et de farnesyl-pyrophosphate synthase dans la preparation d'un medicament
BRPI0821962A2 (pt) * 2008-01-03 2019-05-07 Univ De La Mediterrannee Aix Marseille Ii composições e métodos usados durante um tratamento anti-hiv
ES2339524B1 (es) * 2008-08-28 2011-03-22 Proyecto De Biomedicina Cima, S.L. Nuevo biomarcador como diana terapeutica en cancer de pulmon.
US9169279B2 (en) 2009-07-31 2015-10-27 Thar Pharmaceuticals, Inc. Crystallization method and bioavailability
US20160016982A1 (en) 2009-07-31 2016-01-21 Thar Pharmaceuticals, Inc. Crystallization method and bioavailability
KR101813728B1 (ko) 2009-07-31 2017-12-29 그뤼넨탈 게엠베하 결정화 방법 및 생체이용률
EP2533764A4 (en) * 2010-02-08 2016-08-31 Univ Nebraska BIOMINERAL AND METAL BINDING LIPOSOME, THEIR SYNTHESIS AND METHOD FOR THE PRODUCTION THEREOF
US9107983B2 (en) 2010-10-27 2015-08-18 Warsaw Orthopedic, Inc. Osteoconductive matrices comprising statins
US8877221B2 (en) 2010-10-27 2014-11-04 Warsaw Orthopedic, Inc. Osteoconductive matrices comprising calcium phosphate particles and statins and methods of using the same
WO2012071517A2 (en) 2010-11-24 2012-05-31 Thar Pharmaceuticals, Inc. Novel crystalline forms
WO2012170417A2 (en) 2011-06-06 2012-12-13 Warsaw Orthopedic, Inc. Methods and compositions to enhance bone growth comprising a statin
US10195218B2 (en) 2016-05-31 2019-02-05 Grunenthal Gmbh Crystallization method and bioavailability

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999045923A1 (en) * 1998-03-13 1999-09-16 Merck & Co., Inc. Methods of inhibiting bone resorption
CN1306515A (zh) * 1998-05-12 2001-08-01 沃尼尔·朗伯公司 蛋白质法尼基转移酶与HMG CoA还原酶抑制剂的组合及其治疗癌症的用途
US20010025028A1 (en) * 1998-03-13 2001-09-27 Merck & Co., Inc. Methods of inhibiting bone resorption
US20020028826A1 (en) * 2000-06-15 2002-03-07 Robl Jeffrey A. HMG-CoA reductase inhibitors and method
WO2002028270A2 (en) * 2000-10-06 2002-04-11 Probiochem, Llc The treatment of cancer utilizing a cox-2 inhibitor and a hmg-coa reductase inhibitor
US20020061901A1 (en) * 2000-06-15 2002-05-23 Robl Jeffrey A. HMG-CoA reductase inhibitors and method

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6080779A (en) * 1996-12-13 2000-06-27 Osteoscreen, Inc. Compositions and methods for stimulating bone growth

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999045923A1 (en) * 1998-03-13 1999-09-16 Merck & Co., Inc. Methods of inhibiting bone resorption
US20010025028A1 (en) * 1998-03-13 2001-09-27 Merck & Co., Inc. Methods of inhibiting bone resorption
CN1306515A (zh) * 1998-05-12 2001-08-01 沃尼尔·朗伯公司 蛋白质法尼基转移酶与HMG CoA还原酶抑制剂的组合及其治疗癌症的用途
US20020028826A1 (en) * 2000-06-15 2002-03-07 Robl Jeffrey A. HMG-CoA reductase inhibitors and method
US20020061901A1 (en) * 2000-06-15 2002-05-23 Robl Jeffrey A. HMG-CoA reductase inhibitors and method
WO2002028270A2 (en) * 2000-10-06 2002-04-11 Probiochem, Llc The treatment of cancer utilizing a cox-2 inhibitor and a hmg-coa reductase inhibitor

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
Bisphosphonate treatment inhibits the growth of prostatecancer cells Margaret V. Lee et al,Cancer research,Vol.61 2001 *
Bisphosphonates induce apoptosis in human breast cancercell lines SG Senaratne et al,British Journal of Cancer,Vol.82 No.8 2000 *
HMG-COA还原酶抑制剂对胃癌细胞增殖的影响 丁小云等，癌症，第20卷第5期 2001 *

Also Published As

Publication number Publication date
US20060234985A1 (en) 2006-10-19
HK1080734A1 (en) 2006-05-04
AU2003270154A1 (en) 2004-04-30
CN1681515A (zh) 2005-10-12
EP1539186A1 (en) 2005-06-15
BR0314081A (pt) 2005-07-05
WO2004024165A1 (en) 2004-03-25
US20090209493A1 (en) 2009-08-20
JP2006500401A (ja) 2006-01-05
CA2497182A1 (en) 2004-03-25
GB0220885D0 (en) 2002-10-16

Similar Documents

Publication Publication Date Title
US20090209493A1 (en) Combination therapy comprising a bisphosphonate and a hmg-coa reductase inhibitor
CA2427161C (en) Use of bisphosphonates for pain treatment
AU2002257802B2 (en) Use of bisphosphonates in the treatment of bone metastasis associated with prostate cancer
AU2001274109B2 (en) Method of administering bisphosphonates
AU2002257802A1 (en) Use of bisphosphonates in the treatment of bone metastasis associated with prostate cancer
AU2002217061A1 (en) Use of bisphosphonates for pain treatment
US20080227755A1 (en) Method of administering bisphosphonates
AU670337B2 (en) Use of certain methanebisphosphonic acid derivatives in fracture healing
HK1080734B (en) Combination therapy comprising a bisphosphonate and a hmg-coa reductase inhibitor
HK1068550A (en) Use of bisphosphonates for pain treatment
HK1080733B (en) Pharmaceutical composition for use for the treatment of malignancies comprising in combination a bisphosphonates,a cox-2 inhibitor and a taxol
HK1080733A1 (en) Pharmaceutical composition for use for the treatment of malignancies comprising in combination a bisphosphonates,a cox-2 inhibitor and a taxol

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1080734

Country of ref document: HK

C14 Grant of patent or utility model
GR01 Patent grant
C17 Cessation of patent right
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20070725

Termination date: 20100908